Autoantibody profiling to predict response to the anti-PD-1 therapy, pembrolizumab, in rare tumors [0.03%]
预测派姆单抗抗PD-1治疗罕见肿瘤反应的自身抗体谱分析
M H Derbala,J Hajjar,B Stephen et al.
M H Derbala et al.
Background: Immune checkpoint inhibitors (ICIs) have limited response rates in selected patients and can cause potentially life-threatening immune-related adverse events (irAEs). This underscores the urgent need for the d...
Health-related quality of life and performance status with NALIRIFOX versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma: results from the NAPOLI 3 trial [0.03%]
一线治疗转移性胰腺导管腺癌患者中,NALIRIFOX与白蛋白紫杉醇+吉西他滨在健康相关生活质量及体能状态方面的对比:NAPOLI-3研究结果
D Melisi,T Macarulla,C De La Fouchardière et al.
D Melisi et al.
Background: In NAPOLI 3 (NCT04083235), first-line (1L) liposomal irinotecan plus 5-fluorouracil/leucovorin plus oxaliplatin (NALIRIFOX) demonstrated statistically significant improvements in overall survival and progressi...
Neoadjuvant immunotherapy for nonmetastatic dMMR/MSI colon cancer: a real-world retrospective AGEO study [0.03%]
错配修复缺陷/微卫星不稳定型结肠癌新辅助免疫治疗的真实世界回顾性AGEO研究
C Lemaire,A Boileve,G Manceau et al.
C Lemaire et al.
Background: Several studies showed that in mismatch repair-deficient (dMMR)/microsatellite instability (MSI) nonmetastatic colon cancer (CC), neoadjuvant immune checkpoint inhibitors (ICIs) were associated with exceptiona...
Molecular profile and clinical impact of MDM2 amplification in patients with advanced biliary tract cancer [0.03%]
胆管癌患者MDM2扩增的分子分型及临床意义
H Yoon,H Jeong,I Park et al.
H Yoon et al.
Background: MDM2, a negative regulator of p53, has emerged as a potential therapeutic target as its inhibition can restore p53 tumor suppressor activity in MDM2-amplified tumors, including subsets of biliary tract cancer ...
A phase I study of the CSF1R inhibitor vimseltinib in combination with the PD-L1 inhibitor avelumab in patients with advanced sarcoma [0.03%]
维姆西替尼联合阿维鲁单抗治疗晚期软组织肉瘤的I期研究
E Rosenbaum,K Seier,M Bradic et al.
E Rosenbaum et al.
Background: Sarcomas are frequently infiltrated with immunosuppressive myeloid cells. Vimseltinib is an inhibitor of the colony-stimulating factor 1 receptor kinase and has been shown to decrease tumor-infiltrating myeloi...
Effectiveness of post-trastuzumab deruxtecan treatments and incidence of interstitial lung disease in HER2-positive metastatic breast cancer: a real-world, observational cohort study [0.03%]
针对HER2阳性转移性乳腺癌患者接受T-DM1治疗后的疗效及间质性肺疾病发病率的观察性队列研究
K Nozawa,H Iwata,T Mukohara et al.
K Nozawa et al.
Background: Trastuzumab deruxtecan (T-DXd) is recommended in the second-line or later setting for patients with human epidermal growth factor receptor 2 (HER2)-positive recurrent or metastatic breast cancer (mBC). However...
Tislelizumab plus nab-paclitaxel and cisplatin as induction immunochemotherapy for organ preservation of locally advanced hypopharyngeal squamous cell carcinoma: a single-arm phase II trial [0.03%]
替雷利珠单抗联合白蛋白结合型紫杉醇和顺铂作为晚期下咽鳞癌器官保护诱导免疫化疗的II期单臂临床试验
L Gui,Z Xie,W Zhang et al.
L Gui et al.
Introduction: Hypopharyngeal squamous cell carcinoma (HPSCC) has the poorest prognosis among head and neck cancer subtypes. The efficacy, role in organ preservation, safety, and biomarkers of induction immunochemotherapy ...
Circulating tumor DNA mutational landscape and dynamics after progression on a CDK4/6 inhibitor in the PACE phase II trial for metastatic HR-positive/HER2-negative breast cancer [0.03%]
帕克二期临床试验中绝经后HR阳性/her2阴性转移性乳腺癌患者在使用CDK4/6抑制剂治疗进展后的循环肿瘤DNA突变景观和动态变化分析
R Jeselsohn,J Fu,Y Ren et al.
R Jeselsohn et al.
Background: Genomic determinants of response and resistance to endocrine therapy (ET) and cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) beyond progression in hormone receptor-positive/human epidermal growth factor rece...
Genetic testing for BRCA1/2 variants in Northern African women with ovarian and breast cancers: a multicentre study of an under-represented ancestry [0.03%]
北非卵巢癌和乳腺癌患者中BRCA1/2变异的基因检测:一项代表性不足的人群的多中心研究
K S Shohdy,L Kassem,T Elnahas et al.
K S Shohdy et al.
Background: There is a lack of studies investigating the burden of BRCA1/2 pathogenic variants (PVs) in Northern African countries using next-generation sequencing (NGS)-based testing in patients with epithelial ovarian (...
Impact of the Prosigna assay on neoadjuvant treatment decision-making in patients with early-stage HR-positive/HER2-negative breast cancer: a single-center prospective observational study [0.03%]
Prosigna检测对HR阳性/HER2阴性早期乳腺癌患者新辅助治疗决策影响的单中心前瞻性观察研究
C Corti,X Chu,P Exman et al.
C Corti et al.
Background: The 50-gene assay Prosigna is cleared by the United States Food and Drug Administration only in postoperative hormone receptor-positive (HR-positive) breast cancer (BC) specimens. Given studies showing that Pr...